1492 Capital Management LLC Acquires Shares of 49,086 ADMA Biologics Inc (NASDAQ:ADMA)

1492 Capital Management LLC acquired a new position in ADMA Biologics Inc (NASDAQ:ADMA - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 49,086 shares of the biotechnology company's stock, valued at approximately $974,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ADMA. Vanguard Group Inc. increased its holdings in ADMA Biologics by 0.4% during the 4th quarter. Vanguard Group Inc. now owns 18,198,796 shares of the biotechnology company's stock valued at $312,109,000 after purchasing an additional 80,302 shares during the period. Geode Capital Management LLC lifted its holdings in shares of ADMA Biologics by 0.9% during the fourth quarter. Geode Capital Management LLC now owns 5,432,384 shares of the biotechnology company's stock valued at $93,187,000 after purchasing an additional 50,399 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of ADMA Biologics by 16.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,668,320 shares of the biotechnology company's stock valued at $80,065,000 after purchasing an additional 643,661 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of ADMA Biologics by 2.8% during the fourth quarter. Renaissance Technologies LLC now owns 3,769,888 shares of the biotechnology company's stock valued at $64,654,000 after purchasing an additional 102,692 shares during the last quarter. Finally, Oberweis Asset Management Inc. lifted its holdings in shares of ADMA Biologics by 15.0% during the fourth quarter. Oberweis Asset Management Inc. now owns 3,342,560 shares of the biotechnology company's stock valued at $57,325,000 after purchasing an additional 435,480 shares during the last quarter. 75.68% of the stock is currently owned by hedge funds and other institutional investors.

ADMA Biologics Stock Up 4.0%

Shares of ADMA traded up $0.70 on Friday, hitting $18.01. 3,276,489 shares of the stock traded hands, compared to its average volume of 2,444,680. The company has a market capitalization of $4.30 billion, a PE ratio of 30.91 and a beta of 0.43. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.36 and a current ratio of 6.58. The business has a 50 day simple moving average of $19.01 and a 200 day simple moving average of $18.73. ADMA Biologics Inc has a one year low of $10.21 and a one year high of $25.67.

ADMA Biologics (NASDAQ:ADMA - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.16 by ($0.02). The firm had revenue of $114.80 million for the quarter, compared to the consensus estimate of $116.40 million. ADMA Biologics had a net margin of 45.01% and a return on equity of 47.16%. ADMA Biologics's revenue was up 40.2% on a year-over-year basis. During the same period last year, the business earned $0.08 EPS. As a group, equities analysts forecast that ADMA Biologics Inc will post 0.51 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ADMA. Wall Street Zen lowered shares of ADMA Biologics from a "hold" rating to a "sell" rating in a report on Friday, May 9th. Raymond James Financial lifted their target price on shares of ADMA Biologics from $25.00 to $32.00 and gave the company a "strong-buy" rating in a report on Thursday, May 8th.

Insider Buying and Selling

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 20,000 shares of the stock in a transaction that occurred on Monday, June 9th. The shares were sold at an average price of $20.96, for a total value of $419,200.00. Following the transaction, the director directly owned 94,830 shares in the company, valued at approximately $1,987,636.80. This trade represents a 17.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Steve Elms sold 194,749 shares of the stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $20.24, for a total transaction of $3,941,719.76. Following the completion of the transaction, the director owned 87,330 shares in the company, valued at $1,767,559.20. The trade was a 69.04% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 464,621 shares of company stock worth $9,644,269. 3.50% of the stock is owned by insiders.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.